MBX Biosciences Change in Accounts Receivable 2023-2025 | MBX

MBX Biosciences change in accounts receivable from 2023 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

MBX Biosciences Change in Accounts Receivable 2023-2025 | MBX

MBX Biosciences change in accounts receivable from 2023 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$222.7B
Amgen (AMGN)$161.5B
Gilead Sciences (GILD)$142.5B
Vertex Pharmaceuticals (VRTX)$123.1B
Bristol Myers Squibb (BMY)$98.7B
GSK (GSK)$81B
CSL (CSLLY)$78.2B
Regeneron Pharmaceuticals (REGN)$60.4B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$34.4B
BioNTech SE (BNTX)$27.4B
Royalty Pharma (RPRX)$20.3B
Biogen (BIIB)$19.8B
Insmed (INSM)$18.3B
Illumina (ILMN)$15.8B
Genmab (GNMSF)$14B
Genmab (GMAB)$14B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.3B
Exelixis (EXEL)$12.3B
BioMarin Pharmaceutical (BMRN)$11.3B
QIAGEN (QGEN)$10.8B
Ascendis Pharma (ASND)$10.8B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Regencell Bioscience Holdings (RGC)$8.2B
Roivant Sciences (ROIV)$7.9B